Finerenone After Recent Worsening Heart Failure: A FINEARTS-HF Analysis
ABSTRACT:
Study at a glance
- Publication type: Randomized, double-blind, placebo-controlled trial analysis
- What it examined: This FINEARTS-HF analysis examined finerenone in people with heart failure and left ventricular ejection fraction of at least 40%, according to how recently a worsening heart failure event had occurred.
- Key point: Recent worsening heart failure identified a group at higher risk of recurrent heart failure events and cardiovascular death. The authors reported a possible signal of greater absolute benefit with finerenone in this group and stated that it requires confirmation.
Why it matters
A subgroup analysis can be clinically informative, but it should be read as exploratory unless confirmed in future work. Safety monitoring remains central to use of mineralocorticoid receptor antagonists.
Source
Desai AS, et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol. 2025;85:106-116. PMID: 39352340. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.
